Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Sigma Healthcare Reports Full Year 2020/2021 ASX Release

23 Mar 2021  |  09:16:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Sigma Full Year 2020/2021 ASX Release

Sigma Healthcare Reported EBITDA of $94.2m for FY 2021, up 289.2% on the prior year 2020, with Underlying EBITDA of $81.1m up 39.2%, which is slightly ahead of the guidance provided on 8 February 2021. Group Revenue for FY 2021 benefited from a combination of organic growth from its core wholesale sales and pharmacy brands, along with new business. Sales to Chemist Warehouse reached full annualised run rate by June 2020 and remains on track to achieve $800m sales over a 12-month period.

Please click here for full details

See more ASX300 News Announcements